Published in J Immunol on April 01, 1983
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A (1985) 7.15
Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci U S A (1984) 4.43
Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med (1984) 4.00
Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest (1985) 3.40
Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells. J Exp Med (1983) 2.93
Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med (1984) 2.33
Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun (1989) 2.13
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81
Natural killer cells activated in a human mixed lymphocyte response culture identified by expression of Leu-11 and class II histocompatibility antigens. J Exp Med (1984) 1.80
Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 1.76
Use of monoclonal antibodies as sensitive and specific probes for biologically active human gamma-interferon. Proc Natl Acad Sci U S A (1984) 1.72
Differential regulation of HLA-DR mRNAs and cell surface antigens by interferon. EMBO J (1983) 1.71
Immune interferon and leukocyte-conditioned medium induce normal and leukemic myeloid cells to differentiate along the monocytic pathway. J Exp Med (1983) 1.69
Organization of the transcriptional unit of a human class II histocompatibility antigen: HLA-DR heavy chain. Nucleic Acids Res (1983) 1.65
Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci U S A (1993) 1.64
Interferon-gamma depresses binding of ligand by C3b and C3bi receptors on cultured human monocytes, an effect reversed by fibronectin. J Exp Med (1986) 1.64
Human macrophage activation. Modulation of mannosyl, fucosyl receptor activity in vitro by lymphokines, gamma and alpha interferons, and dexamethasone. J Clin Invest (1985) 1.59
Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med (1994) 1.46
Trans-acting element(s) operating across species barriers positively regulate expression of major histocompatibility complex class II genes. J Exp Med (1985) 1.39
Decreased expression of human class II antigens on monocytes from patients with acquired immune deficiency syndrome. Increased expression with interferon-gamma. J Clin Invest (1984) 1.36
Autogenous production of interferon-beta switches on HLA genes during differentiation of histiocytic lymphoma U937 cells. EMBO J (1984) 1.31
Gamma-interferon induces expression of the HLA-D antigens on normal and leukemic human myeloid cells. Proc Natl Acad Sci U S A (1984) 1.29
Human chromosomes 6 and 21 are required for sensitivity to human interferon gamma. Proc Natl Acad Sci U S A (1987) 1.25
Interferon gamma upregulates its own gene expression in mouse peritoneal macrophages. J Exp Med (1994) 1.24
Transcriptional enhancers in the HLA-DQ subregion. Mol Cell Biol (1987) 1.24
Molecular cloning of a gene selectively induced by gamma interferon from human macrophage cell line U937. Mol Cell Biol (1989) 1.23
Three distinct signals can induce class II gene expression in a murine pre-B-cell line. Proc Natl Acad Sci U S A (1986) 1.22
Prevention by gamma interferon of fatal infection with Listeria monocytogenes in mice treated with cyclosporin A. Infect Immun (1988) 1.21
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20
HLA class II regulation and structure. Analysis with HLA-DR3 and HLA-DP point mutants. J Exp Med (1985) 1.19
Autocrine secretion of tumor necrosis factor under the influence of interferon-gamma amplifies HLA-DR gene induction in human monocytes. Proc Natl Acad Sci U S A (1988) 1.17
Altered cytokine production and impaired antimycobacterial immunity in protein-malnourished guinea pigs. Infect Immun (1998) 1.17
Differential expression of Ia molecules by human monocytes. J Clin Invest (1984) 1.15
Stereospecific alignment of the X and Y elements is required for major histocompatibility complex class II DRA promoter function. Mol Cell Biol (1991) 1.12
Monoclonal antibodies detect monocyte/macrophage activation and differentiation antigens and identify functionally distinct subpopulations of human rheumatoid synovial tissue macrophages. Am J Pathol (1991) 1.11
Extracellular matrix-modulated expression of human cell surface glycoproteins A42 and J143. Intrinsic and extrinsic signals determine antigenic phenotype. J Exp Med (1986) 1.11
Modulation of monocyte complement synthesis by interferons. Biochem J (1987) 1.08
The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol (1987) 1.07
Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-gamma: abrogation of immune response defect to a T-cell-dependent antigen. Immunology (1996) 1.07
Recognition of rabies and rabies-related viruses by T cells derived from human vaccine recipients. J Virol (1988) 1.05
Purification and characterization of the human interferon-gamma receptor from placenta. Proc Natl Acad Sci U S A (1988) 1.04
Immune aspects of sarcoidosis. Postgrad Med J (1988) 1.04
Cytokines involved in interferon-gamma production by human macrophages. J Innate Immun (2009) 1.03
Phenotypic and functional changes in alveolar macrophages contribute to the pathogenesis of pulmonary sarcoidosis. Clin Exp Immunol (1988) 1.03
Expression of major histocompatibility antigens in human chronic pancreatitis. Gut (1993) 1.03
Supernatants of human leukocytes contain mediator, different from interferon gamma, which induces expression of MHC class II antigens. J Exp Med (1986) 1.02
Functional anatomy of the thymic microenvironment. J Anat (1991) 1.00
Lymphocyte major histocompatibility complex-encoded class II structures may act as sperm receptors. Proc Natl Acad Sci U S A (1987) 1.00
Study of T-lymphocyte subsets of healthy and Mycobacterium avium subsp. paratuberculosis-infected cattle. Infect Immun (1997) 0.99
Human interferon-gamma induces expression of HLA-DR on keratinocytes and melanocytes. Arch Dermatol Res (1985) 0.99
Induction of murine gamma interferon production by lipopolysaccharide and interleukin-2 in Propionibacterium acnes-induced peritoneal exudate cells. Infect Immun (1987) 0.97
Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol (1989) 0.96
Influence of 1,25-(OH)2 vitamin D3 and gamma interferon on the phenotype of human peripheral blood monocyte-derived macrophages. Infect Immun (1987) 0.96
Recombinant human gamma interferon enhances in vitro activation of lymphocytes isolated from patients with acquired immunodeficiency syndrome. Infect Immun (1989) 0.94
Inherited immunodeficiency with a defect in a major histocompatibility complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene. Mol Cell Biol (1989) 0.94
Defective intralesional interferon-gamma activity in patients with lepromatous leprosy. Clin Exp Immunol (1988) 0.94
Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation. Mol Cell Biol (1986) 0.94
Calcium influx and the Ca2+-calmodulin complex are involved in interferon-gamma-induced expression of HLA class II molecules on HL-60 cells. Proc Natl Acad Sci U S A (1988) 0.92
Modulation by interferons of the expression of monocyte complement genes. Biochem J (1990) 0.92
Suppression by human recombinant gamma interferon of in vitro macrophage nonopsonic and opsonic phagocytosis and killing. Infect Immun (1991) 0.92
Glucocorticoid enhances gamma interferon effects on human monocyte antigen expression and ADCC. Clin Exp Immunol (1986) 0.91
Class II MHC antigen expression by human keratinocytes results from lympho-epidermal interactions and gamma-interferon production. Clin Exp Immunol (1986) 0.90
Abnormal urothelial HLA-DR expression in interstitial cystitis. Clin Exp Immunol (1992) 0.89
Mechanisms of macrophage activation in rheumatoid arthritis: the role of gamma-interferon. Clin Exp Immunol (1986) 0.88
Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example. BioDrugs (2013) 0.88
Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. Clin Exp Immunol (1987) 0.87
CD14 expression in injured patients correlates with outcome. Ann Surg (1996) 0.87
Immunological effects of insulin-like growth factor-I--enhancement of immunoglobulin synthesis. Clin Exp Immunol (1994) 0.86
Interferon gamma and granulocyte/macrophage colony-stimulating factor inhibit growth and induce antigens characteristic of myeloid differentiation in small-cell lung cancer cell lines. Proc Natl Acad Sci U S A (1986) 0.85
Enhanced expression in vivo of HLA-ABC antigens and beta 2-microglobulin on human lymphoid cells induced by human interferon-alpha in patients with lung cancer. Enhanced expression of class I major histocompatibility antigens prior to treatment. Clin Exp Immunol (1985) 0.84
Gamma interferon-mediated increase in the number of Ia-bearing macrophages during infection with Listeria monocytogenes. Infect Immun (1987) 0.83
Recombinant gamma interferon induces HLA-DR expression on squamous cell carcinoma, trichilemmoma, adenocarcinoma cell lines, and cultured human keratinocytes. Arch Dermatol Res (1987) 0.83
Induction of HLA-DR antigen expression in human endometrial epithelial cells in vitro by recombinant gamma-interferon. Am J Pathol (1986) 0.83
Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol (2011) 0.83
M5, a phosphoinositol-linked human myelomonocytic activation-associated antigen. Clin Exp Immunol (1990) 0.83
Effect of interferons (rIFN-alpha 2, rIFN-gamma) on DNA-synthesis and HLA-DR expression in psoriasis. Arch Dermatol Res (1986) 0.82
Chemical characterization of an interleukin-1-inducing substance derived from human mixed leukocyte reactions: IL-1-inducing substance is not gamma interferon. Yale J Biol Med (1985) 0.82
Suppression of HLA class II expression on thyrocytes by interferon-alpha 1. Clin Exp Immunol (1990) 0.80
Cytokines as biological response modifiers. J Clin Pathol (1992) 0.79
Interferons modulate the expression of hormone receptors on the surface of murine melanoma cells. J Clin Invest (1989) 0.79
The expression of class II MHC gene products by fallopian tube epithelium in pregnancy and throughout the menstrual cycle. Immunology (1987) 0.79
Inhibitory effect of a human T cell hybrid factor on both cell growth and mixed lymphocyte reactivity. Correlation with class II molecule expression. J Clin Invest (1985) 0.79
Hyperexpression of interferon-gamma-induced MHC class II genes associated with reorganization of the cytoskeleton. Am J Pathol (1991) 0.79
Cytokine regulation of HLA on thyroid epithelial cells. Clin Exp Immunol (1990) 0.78
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma. Clin Exp Immunol (1990) 0.77
Tumor necrosis factor alpha response elements in the HLA-DRA promoter: identification of a tumor necrosis factor alpha-induced DNA-protein complex in astrocytes. Proc Natl Acad Sci U S A (1992) 0.76
A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells. Front Immunol (2016) 0.75
Transcriptome Profiling of IL-17A Preactivated Mesenchymal Stem Cells: A Comparative Study to Unmodified and IFN-γ Modified Mesenchymal Stem Cells. Stem Cells Int (2017) 0.75
Monocyte human leukocyte antigen-DR expression-a tool to distinguish intestinal bacterial infections from inflammatory bowel disease? Shock (2013) 0.75
The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals. Clin Exp Immunol (1990) 0.75
A suppressor lymphokine produced by human T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells. J Exp Med (1986) 0.75
Dissection of macrophage tumoricidal and protozoacidal activities using T-cell hybridomas and recombinant lymphokines. Infect Immun (1985) 0.75
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med (1983) 3.83
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med (1998) 3.55
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol (1991) 3.32
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Concerning the mechanism of action of interferon. Proc Natl Acad Sci U S A (1966) 3.15
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
On-line computer quality control of antibiotic-sensitivity testing. N Engl J Med (1970) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 2.80
Inhibition of TRIC agents by virus-induced interferon. Proc Soc Exp Biol Med (1966) 2.78
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Physical properties of human interferon prepared in vitro and in vivo. Virology (1966) 2.62
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 2.32
Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. J Infect Dis (1982) 2.29
Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest (1985) 2.28
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
Interferon inducers in vitro: difference in sensitivity to inhbitiros of RNA and protein synthesis. Science (1968) 2.16
Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology (1988) 2.14
Cellular immunity and herpesvirus infections in cardiac-transplant patients. N Engl J Med (1977) 2.09
Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. J Immunol (1975) 2.09
Measles in adults. An unforeseen consequence of immunization? JAMA (1976) 2.08
Patient compliance and drug failure in protease inhibitor monotherapy. JAMA (1996) 2.06
Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med (1978) 2.04
Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers. Virology (1968) 1.96
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Induction of circulating interferon by synthetic anionic polymers of known composition. Nature (1967) 1.92
Interferon and cytomegalovirus in vivo and in vitro. Proc Soc Exp Biol Med (1967) 1.85
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest (1991) 1.85
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis (1995) 1.77
The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon. J Clin Invest (1971) 1.75
PPD-stimulated interferon: in vitro macrophage-lymphocyte interaction in the production of a mediator of cellular immunity. Cell Immunol (1971) 1.75
Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol (1997) 1.74
Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med (1973) 1.73
A useful quantitative semimicromethod for viral plaque assay. Proc Soc Exp Biol Med (1973) 1.73
Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Proc Natl Acad Sci U S A (1972) 1.73
Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J Virol (1985) 1.73
Viral infections in man associated with acquired immunological deficiency states. Fed Proc (1972) 1.70
Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes. J Clin Microbiol (1995) 1.69
An artificial intelligence program to advise physicians regarding antimicrobial therapy. Comput Biomed Res (1973) 1.69
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS (1999) 1.68
Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus. Infect Immun (1976) 1.67
Interferon, antibody, and other host factors in herpes zoster. J Clin Invest (1972) 1.64
The immunosuppressive effect of type II mouse interferon preparations on antibody production. Cell Immunol (1977) 1.64
Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. J Immunol (1974) 1.60
Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol (1984) 1.60
Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med (1984) 1.58
Bis-DEAE-fluorenone: mechanism of antiviral protection and stimulation of interferon production in the mouse. J Infect Dis (1971) 1.56
Herpes Zoster-Varicella infections and lymphoma. Ann Intern Med (1972) 1.54
Current concepts of interferon and interferon induction. Annu Rev Med (1970) 1.53
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation (1999) 1.52
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis (1978) 1.51
Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology (1981) 1.49
Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to Herpes simplex antigen. J Immunol (1975) 1.49
The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86. Virology (1989) 1.49
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol (1997) 1.48
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol (1995) 1.48
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
Hereditary occurrence of cystic disease of the renal medulla. N Engl J Med (1966) 1.46
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr (1994) 1.44
Diagnosis of cytomegalovirus pneumonia in compromised hosts. Am J Med (1976) 1.44
Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med (1978) 1.44
Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Cell Immunol (1978) 1.43
Requirement of a stable secondary structure for the antiviral activity of polynucleotides. Nature (1969) 1.43
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis (1991) 1.43
Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med (1978) 1.42
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother (1997) 1.42
Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA (1982) 1.42
Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum (1981) 1.41
Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. J Infect Dis (1974) 1.40
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis (1978) 1.40
Resistance to virus challenge in mice infected with protozoa or bacteria. Proc Soc Exp Biol Med (1969) 1.40
Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations. Ann Intern Med (1980) 1.39
Toxicity of vidarabine. JAMA (1979) 1.39
In vitro production and cellular origin of murine type II interferon. Immunology (1979) 1.39
Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. Lab Invest (1984) 1.38
Septicemia with Pasteurella pseudotuberculosis and liver disease. Arch Intern Med (1971) 1.37
Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis (1981) 1.36
Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans. Proc Natl Acad Sci U S A (1978) 1.35
Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia. N Engl J Med (1970) 1.34
Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus. Proc Natl Acad Sci U S A (1989) 1.34
Effect of vidarabine on chronic hepatitis B virus infection. JAMA (1978) 1.34
gamma Interferon production appears to predict time of recurrence of herpes labialis. J Immunol (1983) 1.32
Pharmacokinetics of rifabutin. Antimicrob Agents Chemother (1989) 1.30